

Substitute for form 1449A/PTO

## STATEMENT BY APPLICANT

(use ~~5~~ many sheets as necessary)

1

of

3

**COMPLETE IF KNOWN**

<b>Application Number</b>	10/501,999
<b>Filing Date</b>	July 20, 2004
<b>First Named Inventor</b>	Richard N. Pierson III
<b>Group Art Unit</b>	1614
<b>Examiner Name</b>	Fay, Zohreh A.
<b>Attorney Docket Number</b>	21067YP

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

Examiner  
Signature

/Gregg Polansky/


Date Considered

06/01/2008

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and note considered. Include copy of this form with next communication if applicable. **EXCERPTS FROM THE PRIOR ART ARE NOT TO BE REPRODUCED IN THE DRAWINGS OR IN THE DESCRIPTION.**

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003

Substitute for form 1449/BPTO		<b>COMPLETE IF KNOWN</b>	
<b>INFORMATION DISCLOSURE</b>		<b>Application Number</b>	10/501,999
<b>STATEMENT BY APPLICANT</b>		<b>Filing Date</b>	July 20, 2004
		<b>First Named Inventor</b>	Richard N. Pierson III
		<b>Group Art Unit</b>	1614
		<b>Examiner Name</b>	Fay, Zohreh A.
		<b>Attorney Docket Number</b>	21067YP
Sheet	2	of	5

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
	11	Segerer, S., et al., "The Duffy Antigen Receptor for Chemokines is Up-regulated During Acute Renal Transplant Rejection and Crescentic Glomerulonephritis", <i>Kidney Int.</i> , Vol. 58, No. 4, pp. 1546-1556 (Oct. 2000)
	12	Segerer, S., et al., "Expression of the C-C Chemokine Receptor 5 in Human Kidney Diseases", <i>Kidney Int.</i> , Vol. 56, No. 1, pp. 52-64 (July 1999)
	13	PUBMED Abstract of: Le, Y., et al., "A New Insight into the Role of 'Old' Chemotactic Peptide Receptors FPR and FPRL1: Down-regulation of Chemokine Receptors CCR5 and CXCR4", <i>Forum (Genova)</i> , Vol. 9, No. 4, pp. 299-314 (Oct-Dec 1999)
	14	Zhou, Y., et al., "Impaired Macrophage Function and Enhanced T Cell-Dependent Immune Response in Mice Lacking CCR5, the Mouse Homologue of the Major HIV-1 Coreceptor", <i>Journal of Immunology</i> , Vol. 160, pp. 4018-4025 (1998)
	15	Cascieri, M.A., et al., "The Chemokine/Chemokine-receptor Family: Potential and Progress for Therapeutic Intervention", <i>Chemical Biology</i> , Vol. 4, pp. 420-427 (2000)
	16	Segerer, S., et al., "Expression of Chemokines and Chemokine Receptors During Human Renal Transplant Rejection", <i>Am. J. of Kidney Diseases</i> , Vol. 37, No. 3, pp. 518-531 (March 2001)
	17	Fischereder M., et al., "CC Chemokine Receptor 5 and Renal-transplant Survival", <i>The Lancet</i> , Vol. 357, pp. 1758-1761, (June 2, 2001)
	18	Strieter, R.M., et al., (Commentary) "Chemokine Receptor Polymorphism in Transplantation Immunology: No Longer Just Important in AIDS", <i>The Lancet</i> , Vol. 357, pp. 1725-1726 (June 2, 2001)
	20	Nadeau, K.C., et al., "Sequential Cytokine Dynamics in Chronic Rejection of Rat Renal Allografts: Roles for Cytokines RANTES and MCP-1", <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 92, pp. 8729-8733 (Sept. 1995)
	21	Belperio, J.A., et al., "The Role of the CC Chemokine, RANTES, in Acute Lung Allograft Rejection", <i>The Journal of Immunology</i> , Vol. 165, pp. 461-472 (2000)
	22	Gröne, H.-J., et al., "Met-RANTES Reduces Vascular and Tubular Damage During Acute Renal Transplant Rejection: Blocking Monocyte Arrest and Recruitment", <i>FASEB J.</i> , Vol. 13, pp. 1371-1383 (1999)
	23	Pierson, R.N., et al., "Prolongation of Primate Cardiac Allograft Survival by Treatment with Anti-CD40 Ligand (CD154) Antibody", <i>Transplantation</i> , Vol. 68, No. 11, pp. 1880-1805 (1999)
	24	Netea, M.G., et al., "Circulating Cytokines as Mediators of Fever", <i>Clinical Infectious Diseases</i> , Vol. 31, pp. S178-S184, (2000)
	25	Dinarello, C.A., "Interleukin-1 and Interleukin-1 Antagonism", <i>Blood</i> , Vol. 77, No. 8, pp. 1627-1652 (1991)
	26	Dinarello, C.A., et al., "The Role of Interleukin-1 in Disease", <i>The New England Journal of Medicine</i> , Vol. 328, No. 2, pp. 106-113 (1993)

Examiner Signature	/Gregg Polansky/	Date Considered	06/01/2008
--------------------	------------------	-----------------	------------

Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE

## STATEMENT BY APPLICANT

MAR 16 2005

(use as many sheets as necessary)

PATENT &amp; TRADEMARK OFFICE

## COMPLETE IF KNOWN

Sheet	1	of	5	Application Number	10/501,999
				Filing Date	July 20, 2004
				First Named Inventor	Richard N. Pierson III
				Group Art Unit	1614
				Examiner Name	Fay, Zohreh A.
				Attorney Docket Number	21067YP

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
	27	Dinareello, C.A., "The Interleukin-1 Family: 10 Years of Discovery", The FASEB Journal, Vol. 8, pp. 1314-1325 (1994)
	28	Ikejima, T., et al., "Induction of Human Interleukin-1 by a Product of Staphylococcus aureus Associated with Toxic Shock Syndrome", J. Clin. Invest., Vol. 73, pp. 1312-1320 (1984)
	29	Dinareello, C.A., "Interleukin-1", Rev. Infect. Disease, Vol. 6, No. 1, pp. 51-94 (1984)
	30	Heinrich, P.C., et al., "Interleukin-6 and the Acute Phase Response", Biochem. J., Vol. 265, pp. 621-636 (1990)
	31	Van Snick, J., "Interleukin-6: An Overview", Annual Review of Immunology, Vol. 8, pp. 253-278 (1990)
	32	Hirano, T., et al., "Biological and Clinical Aspects of Interleukin 6", Immunology Today, Vol. 11, No. 12, pp. 443-449 (1990)
	33	Sehgal, P.B., "Interleukin 6 in Infection and Cancer", Proc. Soc. Exp. Biol. Med., Vol. 195, pp. 183-191 (1990)
	34	Grau, G.E., "Implications of Cytokines in Immunopathology: Experimental and Clinical Data.", Eur. Cytokine Net., Vol. 1, No. 4, pp. 203-210 (1990)
	35	Bauer, J., et al., "Interleukin-6 in Clinical Medicine", Annals of Hematology, Vol. 62, No. 6, pp. 203-210 (1991)
	36	Campbell, I. L., et al., "Essential Role for Interferon-gamma and Interleukin-6 in Autoimmune Insulin-dependent Diabetes in NOD/Wehi Mice", J. Clin. Invest., Vol. 87, pp. 739-742 (1991)
	37	Roodman, G.D., et al., "Interleukin 6 - A Potential Autocrine/Paracrine Factor in Paget's Disease of Bone", J. Clin. Invest., Vol. 89, pp. 46-52 (1992)
	38	Shenkin, A., et al., "The Serum Interleukin 6 Response to Elective Surgery", Lymphokine Res., Vol. 8, No. 2, pp. 123-127 (1989)
	39	Pulicino, E.A., et al., "The Relationship Between the Circulating Concentrations of Interleukin 6 (IL-6), Tumor Necrosis Factor (TNF) and the Acute Phase Response to Elective Surgery and Accidental Injury", Lymphokine Res., Vol. 9, No. 2, pp. 231-238 (1990)
	40	Van Oers, M.H.J., et al., "Interleukin 6 (IL-6) in Serum and Urine of Renal Transplant Recipients", Clin. Exp. Immunol., Vol. 71, pp. 314-319 (1988)
	41	Cerami, A., et al., "The Role of Cachectin/TNF in Endotoxic Shock and Cachexia", Immunology Today, Vol. 9, No. 1 (1998)

Examiner Signature	/Gregg Polansky/	Date Considered	06/01/2008
--------------------	------------------	-----------------	------------

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**COMPLETE IF KNOWN**

Sheet	4	of	5	Application Number	10/501,999
				Filing Date	July 20, 2004
				First Named Inventor	Richard N. Pierson III
				Group Art Unit	1614
				Examiner Name	Fay, Zohreh A.
				Attorney Docket Number	21067YP

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
	42	Revel, M. et al., "Interferons: Cytokines in Autoimmunity", in Ciba Foundation Symposium 129, (John Wiley, 1987), pp. 223-233
	43	Cohen, J., "Cytokines as Mediators of Graft-versus-host Disease", Bone Marrow Transplantation, Vol. 3, pp. 193-197 (1988)
	44	Tracey, K.J., et al., "Shock and Tissue Injury Induced by Recombinant Human Cachectin", Science, Vol. 234, pp. 470-474 (1986)
	45	Alexander, H.R., et al., "A Recombinant Human Receptor Antagonist to Interleukin 1 Improves Survival after Lethal Endotoxemia in Mice", The Journal of Experimental Medicine, Vol. 173, pp. 1029-1032 (1991)
	46	Doherty, G.M., et al., "Evidence For IFN-gamma as a Mediator of the Lethality of Endotoxin and Tumor Necrosis Factor-alpha", The Journal of Immunology, Vol. 149, No. 5, pp. 1666-1670 (1992)
	47	Wysocka, M., et al., "Interleukin-12 is Required for Interferon-gamma production and Lethality in Lipopolysaccharide-induced Shock in Mice", Eur. J. Immunol., Vol. 25, pp. 672-676 (1995)
	48	Van Deuren, M., et al., "Cytokines and the Response to Infection", Journal of Pathology, Vol. 168, pp. 349-356 (1992)
	49	Bone, R., "The Pathogenesis of Sepsis", Annals of Internal Medicine, Vol. 115, pp. 457-469 (1991)
	50	Starnes, H. F., et al., "ANTI-IL-6 Monoclonal Antibodies Protect Against Lethal Escherichia coli Infection and Lethal Tumor Necrosis Factor-alpha Challenge in Mice", The Journal of Immunology, Vol. 145, No. 12, pp. 4185-4191 (1990)
	51	Stevens, D., et al., "Sepsis Syndromes and Toxic Shock Syndromes: Concepts in Pathogenesis and a Perspective of Future Treatment Strategies", Cur. Opin. Infect. Dis., Vol. 6, pp. 374-383 (1993)
	52	Beutler, B., et al., "Passive Immunization Against Cachectin/Tumor Necrosis Factor Protects Mice from Lethal Effect of Endotoxin", Science, Vol. 229, pp. 869-871 (1985)
	53	Heinzel, F.P., "The Role of IFN-gamma in the Pathology of Experimental Endotoxemia", The Journal of Immunology, Vol. 145, No. 9, pp. 2920-2924 (1990)
	54	Bozza, M., et al., "Targeted Disruption of Migration Inhibitory Factor Gene Reveals Its Critical Role in Sepsis", J. Exp. Med., Vol. 189, No. 2, pp. 341-346 (1999)
	55	Ohlsson K., et al., "Interleukin-1 Receptor Antagonist Reduces Mortality from Endotoxin Shock", Nature, Vol. 348, pp. 550-552 (1990)
	56	Kelly, J.L., et al., "Is Circulating Endotoxin the Trigger for the Systemic Inflammatory Response Syndrome Seen After Injury?", Annals of Surgery, Vol. 225, No. 5, pp. 530-543 (1997)

Examiner Signature	/Gregg Polansky/	Date Considered	06/01/2008
--------------------	------------------	-----------------	------------

\*Examiner: Initial if reference considered, otherwise no action is in accordance with MPEP 609. Do not check citation if it is not considered and not considered, include copy of this form with next document to be filed.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003

PHENOCES CONSIDERED EXCEPT WHERE LINED THROUGH. /G.P./

[illegible]

\*Examiner: Initial if reference considered whether or not prior art is in accordance with MPEP 609. Draw through citation if not in accordance and not considered. Include copy of this form with next communication to applicant.

REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /G.P./

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), March & Co., Inc., 09/05/2003